Thomas Axelsson has extensive international leadership experience from the life science and medical technology industries. He served as President and CEO of Vitrolife from 2011 to 2023, during which the company developed from a small-cap company into a global leader in reproductive health. He has previously served as President and CEO of the listed companies Artema Medical and Stille and held several senior commercial and management positions at Baxter.
Thomas has extensive board experience from listed and private life science companies. He currently serves as Chairman of C-RAD and Nexpring Health and has previously held board positions in companies including MedCap, Medivir, Boule International and Stille.
Håkan Björklund, MD, PhD, is Associate Professor at Karolinska Institutet and has extensive international leadership experience from the pharmaceutical and life science industries. He served as CEO of Nycomed Pharma from 1999 to 2011 and previously held several senior executive positions at Astra, including President of Astra Draco and Regional Director for Europe.
Håkan has extensive board experience from both listed and private life science and healthcare companies, including Sobi, BONESUPPORT, H. Lundbeck, Coloplast, QIAGEN and Asker Healthcare Group. He was elected Fellow of the Royal Swedish Academy of Engineering Sciences (IVA) in 2022.
Pharmacist by training and brings more than 20 years of experience from the pharmaceutical and life sciences industry. Currently Chief Executive Officer of Oncopeptides AB and Managing Director of Oncopeptides GmbH. Previously held several executive leadership positions within Oncopeptides, including Chief Commercial Officer and Executive Vice President Global Head of Medical Affairs. Prior to joining Oncopeptides, she spent more than 14 years at AstraZeneca in a range of senior leadership roles, most recently Vice President Medical and Regulatory Nordic-Baltic. Brings extensive expertise in drug development, medical affairs, commercialization, market access, regulatory affairs, and international business leadership.
MD, PhD, co-founder of HealthCap, Managing Partner since 1996. Previous experience includes leading ABB Aros Securities Health Care Equity Research Team. Extensive board experience from the life science sector including Q-Med AB, NicOx SA, Jerini AG, Nordic Nanovector ASA and BoneSupport AB.
MSc in Economics and Business from Stockholm School of Economics and brings extensive experience from corporate development in Life Science companies. Experience from executive positions in several Life Science focused investment companies. Currently CFO of Linc AB, a listed investment company focused on product-oriented Life Science companies, where he also is part of the investment team responsible for evaluating new investments as well as supporting existing portfolio companies. Previously he was responsible for the investment activities of MedCap AB and prior to that he worked with corporate finance advisory at Morgan Stanley and UBS Investment Bank in London and Stockholm.
Medical Candidate and Ph.D. in Neurophysiology from the Faculty of Medicine at Lund University, Master of Science in BioMedical Engineering from the University of California San Diego (USA), and an equivalent of five years of full-time studies in Mathematics and Physics at Lund University and LTH (Engineering Physics). Graduate of the Swedish Armed Forces Language School Academy and holds an honorary Doctorate of Technology from Lund University of Technology.
Thirty years of experience as CEO from fast-growing listed and unlisted companies in Life Science and Tech and founder of publicly listed companies in life science such as CellaVision AB and EQL Pharma AB as well as the VC company Fåhraeus Startup and Growth AB. Extensive Board experience, currently Chairman of EQL Pharma AB, FSG Fund II AB and Fåhraeus Startup & Growth AB, Board member of CellaVision AB, Checkin.com Group AB, FlatFrog Laboratories AB, Melius Pharma AB, Bionamic AB and Ossdsign AB.